Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Interim report for the first half of 2023/24 – Correction | ||
By: GlobeNewswire - 05 Feb 2024 | Back to overview list |
|
ANNOUNCEMENT NO. 250 5 February 2024 Interim report for the first half of 2023/24 – Correction In connection with the previously published interim report for the first half of 2023/24 (announcement no. 249), there were errors in the sales and operating results highlights:
The correct is the following:
The above is also corrected in the attached interim report for the first half of 2023/24. Additional information Rasmus Kofoed, CEO Niels Høy Nielsen, CFO Tel.: (+45) 25 51 87 24 About ChemoMetec A/S ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson. ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to www.chemometec.com Attachment |
||
|
||
Copyright 2024 GlobeNewswire | Back to overview list |